Literature DB >> 21855971

A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer.

Claus Høgdall1, Eric T Fung, Ib J Christensen, Lotte Nedergaard, Svend A Engelholm, Anette L Petri, Signe Risum, Lene Lundvall, Christine Yip, Anette T Pedersen, Dorthe Hartwell, Lee Lomas, Estrid V S Høgdall.   

Abstract

BACKGROUND: Previous reports have shown that the proteomic markers apolipoprotein A1, hepcidin, transferrin, inter-alpha trypsin IV internal fragment, transthyretin, connective-tissue activating protein 3 and beta-2 microglobulin may discriminate between a benign pelvic mass and ovarian cancer (OC). The aim was to determine if these serum proteomic biomarkers alone as well as in combination with age and serum CA125, could be helpful in triage of women with a pelvic mass.
METHODS: We included prospectively 144 patients diagnosed with (OC), 40 with a borderline tumor and 469 with a benign tumor. Surface-enhanced laser desorption/ionization time of flight-mass spectrometry was used for analyses. The Danish Index (DK-Index) based on the proteomic data, age and CA125 was developed using logistic regression models.
RESULTS: Multivariate logistic regression analysis demonstrated that the selected proteomic markers, CA125 and age were independent predictors of OC and the combination of these is proposed as the DK-index. A sensitivity (SN) of 99% had a specificity (SP) of 57% for DK-index and 49% for CA125. At a SN of 95%, the SP increased to 81% for DK-index compared to 68% for CA125 alone. For stage I+II the SP was 58% for DK-index and 49% for CA125. For stage III+IV the corresponding values were 94% and 86% respectively.
CONCLUSIONS: The DK-index warrants further evaluation in independent cohorts.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21855971     DOI: 10.1016/j.ygyno.2011.07.018

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  10 in total

Review 1.  Iron overload and altered iron metabolism in ovarian cancer.

Authors:  Stephanie Rockfield; Joseph Raffel; Radhe Mehta; Nabila Rehman; Meera Nanjundan
Journal:  Biol Chem       Date:  2017-08-28       Impact factor: 3.915

2.  Multianalyte assay systems in the differential diagnosis of ovarian cancer.

Authors:  Brian M Nolen; Anna E Lokshin
Journal:  Expert Opin Med Diagn       Date:  2012-03

3.  Cancer diagnostic tools to aid decision-making in primary care: mixed-methods systematic reviews and cost-effectiveness analysis.

Authors:  Antonieta Medina-Lara; Bogdan Grigore; Ruth Lewis; Jaime Peters; Sarah Price; Paolo Landa; Sophie Robinson; Richard Neal; William Hamilton; Anne E Spencer
Journal:  Health Technol Assess       Date:  2020-11       Impact factor: 4.014

4.  Detection of novel biomarkers for ovarian cancer with an optical nanotechnology detection system enabling label-free diagnostics.

Authors:  Simon Kaja; Jill D Hilgenberg; Julie L Collins; Anna A Shah; Debra Wawro; Shelby Zimmerman; Robert Magnusson; Peter Koulen
Journal:  J Biomed Opt       Date:  2012-08       Impact factor: 3.170

5.  The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?

Authors:  Eleftherios P Diamandis
Journal:  BMC Med       Date:  2012-08-09       Impact factor: 8.775

Review 6.  Discovery of new biomarkers for malignant mesothelioma.

Authors:  Jenette Creaney; Ian M Dick; Bruce W S Robinson
Journal:  Curr Pulmonol Rep       Date:  2015

Review 7.  Danish Gynecological Cancer Database.

Authors:  Sarah Mejer Sørensen; Signe Frahm Bjørn; Kirsten Marie Jochumsen; Pernille Tine Jensen; Ingrid Regitze Thranov; Helle Hare-Bruun; Lene Seibæk; Claus Høgdall
Journal:  Clin Epidemiol       Date:  2016-10-25       Impact factor: 4.790

8.  Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies.

Authors:  John F Timms; Elif Arslan-Low; Musarat Kabir; Jenny Worthington; Stephane Camuzeaux; John Sinclair; Joanna Szaub; Babak Afrough; Vladimir N Podust; Evangelia-Ourania Fourkala; Myriam Cubizolles; Florian Kronenberg; Eric T Fung; Aleksandra Gentry-Maharaj; Usha Menon; Ian Jacobs
Journal:  Proteomics Clin Appl       Date:  2014-11-10       Impact factor: 3.494

9.  Potential tumor biomarkers identified in ovarian cyst fluid by quantitative proteomic analysis, iTRAQ.

Authors:  Björg Kristjansdottir; Kristina Levan; Karolina Partheen; Elisabet Carlsohn; Karin Sundfeldt
Journal:  Clin Proteomics       Date:  2013-04-04       Impact factor: 3.988

10.  Serum protein profile at remission can accurately assess therapeutic outcomes and survival for serous ovarian cancer.

Authors:  Jinhua Wang; Ashok Sharma; Sharad A Ghamande; Stephen Bush; Daron Ferris; Wenbo Zhi; Mingfang He; Meiyao Wang; Xiaoxiao Wang; Eric Miller; Diane Hopkins; Michael Macfee; Ruili Guan; Jinhai Tang; Jin-Xiong She
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.